{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:19:45Z","timestamp":1790162385561,"version":"4.1.0"},"reference-count":34,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2015-1279_s_999_w2aab3b8b1b1b7b1aab1c14b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p> Dipeptidyl peptidase IV (DPPIV\/CD26) plays an important role in T cell activation and immune regulation, however the role of this enzyme in early rheumatoid arthritis (eRA) has not been clearly defined. The aim of this study was to determine the serum activity of DPPIV, its expression on peripheral blood mononuclear cells (PBMC) and to examine possible correlations with disease activity (DAS28) in untreated patients with eRA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2015-1279_s_998_w2aab3b8b1b1b7b1aab1c14b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p> The study included 50 patients newly diagnosed with RA, who had not received any corticosteroid or disease modifying antirheumatic drugs (DMARD) therapy and whose conventional radiographs of hands and feet showed no structural damage. The control group consisted of 40 healthy volunteers. Also, 30 patients with chronic RA (cRA) were examined. The serum activity of DPPIV was determined by the direct photometric method, while expression of CD26 on PBMC was determined using flow cytometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2015-1279_s_997_w2aab3b8b1b1b7b1aab1c14b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p> Decreased DPPIV serum activity was detected in patients with eRA and cRA compared to the control group (p=0.024, p&lt;0.0001, respectively). Although, the percentage of overall CD26+ white blood cells (WBC) was significantly decreased in eRA patients (p&lt;0.001), the percentage of CD26+ lymphocytes and monocytes and mean fluorescence intensity of CD26 on these cells in eRA patients showed no significant difference compared to healthy volunteers. DAS28 showed no significant correlation with CD26 expression or DPPIV serum activity, but a significant inverse correlation between the duration of symptoms and DPPIV serum activity was observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2015-1279_s_996_w2aab3b8b1b1b7b1aab1c14b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p> Our results show that a decrease in DPPIV serum activity, but not CD26 expression, is present in an early stage of rheumatoid arthritis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2015-1279","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T21:39:56Z","timestamp":1466890796000},"page":"73-81","source":"Crossref","is-referenced-by-count":18,"title":["Activity and expression of dipeptidyl peptidase IV on peripheral blood mononuclear cells in patients with early steroid and disease modifying antirheumatic drugs na\u00efve rheumatoid arthritis"],"prefix":"10.1515","volume":"55","author":[{"given":"Milica","family":"Grujic","sequence":"first","affiliation":[{"name":"Institute of Rheumatology, Resavska 69, 11000 Belgrade, Serbia , Phone: +381 11 36 00 834, Fax: +381 11 36 12 376"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana Z.","family":"Matic","sequence":"additional","affiliation":[{"name":"Experimental Laboratory, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija Djordjic","family":"Crnogorac","sequence":"additional","affiliation":[{"name":"Experimental Laboratory, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Damjanovic","family":"Velickovic","sequence":"additional","affiliation":[{"name":"Experimental Laboratory, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branka","family":"Kolundzija","sequence":"additional","affiliation":[{"name":"Experimental Laboratory, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar J.","family":"Cordero","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zorica","family":"Juranic","sequence":"additional","affiliation":[{"name":"Experimental Laboratory, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavica","family":"Prodanovic","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Zlatanovic","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Babic","sequence":"additional","affiliation":[{"name":"Institute of Medical Statistics and Informatics, Belgrade, Serbia"},{"name":"School of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nemanja","family":"Damjanov","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Belgrade, Serbia"},{"name":"School of Medicine, University of Belgrade, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"key":"2023033109540086227_j_cclm-2015-1279_ref_001_w2aab3b8b1b1b7b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Lambeir AM, Durinx C, Scharp\u00e9 S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209\u201394.","DOI":"10.1080\/713609354"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_002_w2aab3b8b1b1b7b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Cordero OJ, Salgado FJ, Nogueira M. On the origin of serum CD26 and its altered concentration in cancer patients. Cancer Immunol Immunother 2009;58:1723\u201347.","DOI":"10.1007\/s00262-009-0728-1"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_003_w2aab3b8b1b1b7b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998;161: 55\u201370.","DOI":"10.1111\/j.1600-065X.1998.tb01571.x"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_004_w2aab3b8b1b1b7b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Mati\u0107 IZ, \u0110or\u0111evi\u0107 M, \u0110or\u0111i\u0107 M, Grozdani\u0107 N, Damjanovi\u0107 A, Kolund\u017eija B, et al. Dipeptidyl peptidase IV: serum activity and expression on lymphocytes in different hematological malignancies. Leuk Lymphoma 2013;54:2701\u20136.","DOI":"10.3109\/10428194.2013.782611"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_005_w2aab3b8b1b1b7b1ab2b2b5Aa","unstructured":"Kajiyama H, Kikkawa F, Khin E, Shibata K, Ino K, Mizutani S. Dipeptidyl Peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 2003;63:2278\u201383."},{"key":"2023033109540086227_j_cclm-2015-1279_ref_006_w2aab3b8b1b1b7b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Bank U, Bohr UR, Reinhold D, Lendeckel U, Ansorge S, Malfertheiner P, et al. Inflammatory bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors. Front Biosci 2008;13:3699\u2013713.","DOI":"10.2741\/2960"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_007_w2aab3b8b1b1b7b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Muscat C, Bertotto A, Agea E, Bistoni O, Ercolani R, Tognellini R, et al. Expression and functional role of 1F7 (CD26) antigen on peripheral blood and synovial fluid T cells in rheumatoid arthritis patients. Clin Exp Immunol 1994;98:252\u20136.","DOI":"10.1111\/j.1365-2249.1994.tb06134.x"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_008_w2aab3b8b1b1b7b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int 2001;21:69\u201374.","DOI":"10.1007\/s002960100134"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_009_w2aab3b8b1b1b7b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Ulusoy H, Kamanli A, Ilhan N, Kuru O, Arslan S, Alkan G, et al. Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis. Rheumatol Int 2012;32:3857\u201362.","DOI":"10.1007\/s00296-011-2302-3"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_010_w2aab3b8b1b1b7b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Sromova L, Mareckova H, Sedova L, Balaziova E, Sedo A. Dipeptidyl peptidase-IV in synovial fluid and in synovial fluid mononuclear cells of patients with rheumatoid arthritis. Clin Chim Acta 2010;411:1046\u201350.","DOI":"10.1016\/j.cca.2010.03.034"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_011_w2aab3b8b1b1b7b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Ospelt C, Mertens JC, J\u00fcngel A, Brentano F, Maciejewska-Rodriguez H, Huber LC, et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2010;62:1224\u201335.","DOI":"10.1002\/art.27395"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_012_w2aab3b8b1b1b7b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Herlihy SE, Brown ML, Pilling D, Weeks BR, Myers LK, Gomer RH. Soluble dipeptidyl peptidase IV decreases inflammation in a murine model of arthritis. Arthritis Rheumatol 2015;67:2634\u20138.","DOI":"10.1002\/art.39250"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_013_w2aab3b8b1b1b7b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type17 helper T cells. N Engl J Med 2009;361:888\u201398.","DOI":"10.1056\/NEJMra0707449"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_014_w2aab3b8b1b1b7b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205\u201319.","DOI":"10.1056\/NEJMra1004965"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_015_w2aab3b8b1b1b7b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Casc\u00e3o R, Moura RA, Perp\u00e9tuo I, Canh\u00e3o H, Vieira-Sousa E, Mour\u00e3o AF, et al. Identification of a cytokine network sustaining neutrophil and Th17 activation in untreated early rheumatoid arthritis. Arthritis Res Ther 2010;12:R196.","DOI":"10.1186\/ar3168"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_016_w2aab3b8b1b1b7b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Cordero OJ, Varela-Calvi\u00f1o R, L\u00f3pez-Gonz\u00e1lez T, Calvi\u00f1o-Sampedro C, Vi\u00f1uela JE, Mouri\u00f1o C, et al. CD26 Expression on T helper populations and sCD26 serum levels in patients with rheumatoid arthritis. PLoS One 2015;10:e0131992.","DOI":"10.1371\/journal.pone.0131992"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_017_w2aab3b8b1b1b7b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Mati\u0107 IZ, \u00d0or\u0111i\u0107 M, Grozdani\u0107 N, Damjanovi\u0107 A, Kolund\u017eija B, Eri\u0107-Nikoli\u0107 A, et al. Serum activity of DPPIV and its expression on lymphocytes in patients with melanoma and in people with vitiligo. BMC Immunol 2012;13:48.","DOI":"10.1186\/1471-2172-13-48"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_018_w2aab3b8b1b1b7b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Jarmo\u0142owska B, Bielikowicz K, Iwan M, Sidor K, Kostyra E, Kaczmarski M. Serum activity of dipeptidyl peptidase IV (DPPIV; EC 3.4.14.5) in breast-fed infants with symptoms of allergy. Peptides 2007;28:678\u201382.","DOI":"10.1016\/j.peptides.2006.11.014"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_019_w2aab3b8b1b1b7b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Eri\u0107-Nikoli\u0107 A, Mati\u0107 IZ, Dor\u0111evi\u0107 M, Milovanovi\u0107 Z, Markovi\u0107 I, D\u017eodi\u0107 R, et al. Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors. Immunobiology 2011;216:942\u20136.","DOI":"10.1016\/j.imbio.2011.01.005"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_020_w2aab3b8b1b1b7b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Fan H, Yan S, Stehling S, Marguet D, Schuppan D, Reutter W. Dipeptidyl peptidase IV\/CD26 in T cell activation, cytokine secretion and immunoglobulin production. In: Hildebrandt M, editor. Dipeptidyl aminopeptidases in health and disease. New York: Kluwer Academic\/Plenum Publishers, 2003:165\u201374.","DOI":"10.1007\/0-306-47920-6_20"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_021_w2aab3b8b1b1b7b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Ohnuma K, Takahashi N, Yamochi T, Hosono O, Dang NH, Morimoto C. Role of CD26\/dipeptidyl peptidase IV in human T cell activation and function. Front Biosci 2008;13:2299\u2013310.","DOI":"10.2741\/2844"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_022_w2aab3b8b1b1b7b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Dong RP, Tachibana K, Hegen M, Munakata Y, Cho D, Schlossman SF, et al. Determination of adenosine deaminase binding domain on CD26 and its immunoregulatory effect on T cell activation. J Immunol 1997;159:6070\u20136.","DOI":"10.4049\/jimmunol.159.12.6070"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_023_w2aab3b8b1b1b7b1ab2b2c23Aa","unstructured":"Cuchacovich M, Gatica H, Pizzo SV, Gonzalez-Gronow M. Characterization of human serum dipeptidyl peptidase IV (CD26) and analysis of its autoantibodies in patients with rheumatoid arthritis and other autoimmune diseases. Clin Exp Rheumatol 2001;19:673\u201380."},{"key":"2023033109540086227_j_cclm-2015-1279_ref_024_w2aab3b8b1b1b7b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Proost P, Mahieu F, Schutyser E, Van Damme J. Posttranslational processing of chemokines. Methods Mol Biol 2004;239:27\u201344.","DOI":"10.1385\/1-59259-435-2:27"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_025_w2aab3b8b1b1b7b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Narducci MG, Scala E, Bresin A, Caprini E, Picchio MC, Remotti D, et al. Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26\/dipeptidylpeptidase IV. Blood 2006;107:1108\u201315.","DOI":"10.1182\/blood-2005-04-1492"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_026_w2aab3b8b1b1b7b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Buljevic S, Detel D, Pucar LB, Mihelic R, Madarevic T, Sestan B, et al. Levels of dipeptidyl peptidase IV\/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients. Rheumatol Int 2013;33:2867\u201374.","DOI":"10.1007\/s00296-013-2823-z"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_027_w2aab3b8b1b1b7b1ab2b2c27Aa","unstructured":"Mizokami A, Eguchi K, Kawakami A, Ida H, Kawabe Y, Tsukada T, et al. Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. J Rheumatol 1996;23:2022\u20136."},{"key":"2023033109540086227_j_cclm-2015-1279_ref_028_w2aab3b8b1b1b7b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR. Dipeptidyl peptidase IV activity and\/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 2005;7:253\u201369.","DOI":"10.1186\/ar1852"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_029_w2aab3b8b1b1b7b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol 2012;188: 5438\u201347.","DOI":"10.4049\/jimmunol.1103801"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_030_w2aab3b8b1b1b7b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Tejera-Alhambra M, Casrouge A, de Andr\u00e9s C, Ramos-Medina R, Alonso B, Vega J, et al. Low DPP4 expression and activity in multiple sclerosis. Clin Immunol 2014;150:170\u201383.","DOI":"10.1016\/j.clim.2013.11.011"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_031_w2aab3b8b1b1b7b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Hildebrandt M, Rose M, R\u00fcter J, Salama A, M\u00f6nnikes H, Klapp BF. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand J Gastroenterol 2001;36: 1067\u201372.","DOI":"10.1080\/003655201750422675"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_032_w2aab3b8b1b1b7b1ab2b2c32Aa","unstructured":"Ellingsen T, Hansen I, Thorsen J, Kuno M\u00f8ller B, Tarp U, Jacobsen S, et al. Up-regulated dipeptidyl-peptidase IV (CD26) on monocytes was unaffected by effective DMARD treatment in early steroid and DMARD-naive rheumatoid arthritis. Clin Exp Rheumatol 2012;30:58\u201363."},{"key":"2023033109540086227_j_cclm-2015-1279_ref_033_w2aab3b8b1b1b7b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Ellingsen T, Hornung N, M\u00f8ller BK, Hjelm-Poulsen J, Stengaard-Pedersen K. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand J Immunol 2007;66:451\u20137.","DOI":"10.1111\/j.1365-3083.2007.01966.x"},{"key":"2023033109540086227_j_cclm-2015-1279_ref_034_w2aab3b8b1b1b7b1ab2b2c34Aa","unstructured":"Kullertz G, Boigk J. Dipeptidyl peptidase IV activity in the serum and synovia of patients with rheumatoid arthritis. Z Rheumatol 1986;45:52\u20136."}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2017.55.issue-1\/cclm-2015-1279\/cclm-2015-1279.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1279\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1279\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T10:26:36Z","timestamp":1680258396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2015-1279\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,11,7]]},"published-print":{"date-parts":[[2017,1,1]]}},"alternative-id":["10.1515\/cclm-2015-1279"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2015-1279","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6,24]]}}}